Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial

Arthritis and Rheumatism

Volumn 62, Issue 5, 2010, Pages 1290-1297

  Song, I H ^a   Heldmann, F ^b   Rudwaleit, M ^a   Listing, J ^c   Appel, H ^a   Braun, J ^b   Sieper, J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Centre of Rheumatology Ruhrgebiet   (Germany)

^c German Rheumatism Research Center   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOHISTOLOGY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; DRUG RESISTANCE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951757221     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27383     Document Type: Article

References (53)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-1390
2. Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC Jr, Dijkmans B, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-452
3. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005;64:124-126 (Pubitemid 40075288)
4. Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 2005;64:296-298 (Pubitemid 40193630)
5. Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007;66:419-421 (Pubitemid 46579648)
6. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-2291
7. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-1193 (Pubitemid 34304258)
8. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-670 (Pubitemid 38658395)
9. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
10. Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, et al. Quantitative analyses of sacroiliac biopsies in spondylo-arthropathies: T cells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 2000;59:135-140 (Pubitemid 30305612)
11. Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994;37:1039-1045 (Pubitemid 24222095)
12. Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Kohler D, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006;54:2845-2851 (Pubitemid 44497763)
13. Appel H, Loddenkemper C, Grozdanovic Z, Ebhardt H, Dreimann M, Hempfing A, et al. Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006;8:R143.
14. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445 (Pubitemid 24030569)
15. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806
16. Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368 (Pubitemid 14134775)
17. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-2285
18. Van der Heijde D, Landewe R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008;67:489-493 (Pubitemid 351498429)
19. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483
20. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003;62:20-26 (Pubitemid 36005790)
21. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-559 (Pubitemid 27344490)
22. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, Landewe R, van der Tempel H, Mielants H, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-132
23. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-1886 (Pubitemid 32758236)
24. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-1444 (Pubitemid 39433948)
25. Lukas C, Braun J, van der Heijde D, Hermann KG, Rudwaleit M, Ostergaard M, et al. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J Rheumatol 2007;34:862-870 (Pubitemid 46641400)
26. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581 (Pubitemid 38758544)
27. Emery P, Furst DE, Ferraccioli G, Udell J, van Vollenhoven RF, Rowe K, et al. Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs [abstract]. Arthritis Rheum 2006;54 Suppl:S228.
28. Van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al, and the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-591
29. Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al, for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-2146
30. Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al, for the Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-3236
31. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
32. Peters ND, Ejstrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scand J Rheumatol 1992;21:134-138
33. Rumiantseva OA, Bochkova AG, Liginova E, Kiseleva NM, Pushkova OV, Bunchuk NV. Intravenous high dose glucocorticoids in patients with ankylosing spondylitis. Ter Arkh 2006;78:71-5. In Russian.
34. Richter MB, Woo P, Panayi GS, Trull A, Unger A, Shepherd P. The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis. Clin Exp Immunol 1983;53:51-59 (Pubitemid 13106750)
35. Mintz G, Enriquez RD, Mercado U, Robles EJ, Jimenez FJ, Gutierrez G. Intravenous methylprednisolone pulse therapy in severe ankylosing spondylitis. Arthritis Rheum 1981;24:734-736 (Pubitemid 11099293)
36. Rodriguez-Escalera C, Fernandez-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology (Oxford) 2008;47:1732-1733
37. Schleenbecker SK, Strock Muller K. Improvement of refractory ankylosing spondylitis in response to rituximab: a case report. Ann Rheum Dis 2008;67 Suppl II:ii626.
38. Nocturne G, Dougados M, Constantin A, Richez C, Sellam J, Simon A, et al. Lack of efficacy of rituximab in spondyloarthropathies: data of 8 patients prospectively followed in the French AIR ('Auto-Immunity and Rituximab') registry. Ann Rheum Dis 2009;68 Suppl III:iii626.
39. Wendling D, Auge B, Streit G, Toussirot E, Mathieu S. Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis. Joint Bone Spine 2008;75:510-511
40. Toussaint S, Karrer S, Wassenberg S. Successful treatment of neutrophilic granulomatous dermatitis with rituximab in a patient with rheumatoid arthritis and spondylitis ancylosans: a case report. Ann Rheum Dis 2008;67 Suppl II:ii317.
41. Baeten D, Kruithof E, Breban M, Tak PP. Spondylarthritis in the absence of B lymphocytes. Arthritis Rheum 2008;58:730-733
42. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebocontrolled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-1675 (Pubitemid 36682375)
43. Burmester G, Rudwaleit M, Smith V, Kary S, Kupper H. Effectiveness and safety of adalimumab (humira) therapy after failure of prior TNF-antagonists in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Ann Rheum Dis 2007;66 Suppl II:ii64.
44. Dorner T, Burmester GR. New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 2008;20:263-268 (Pubitemid 351483314)
45. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688 (Pubitemid 351240747)
46. Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol 2008;35:826-833 (Pubitemid 351747123)
47. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-1545 (Pubitemid 41742472)
48. Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67:330-334 (Pubitemid 351281266)
49. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246-250
50. Noel N, Monnet X, Angel N, Goujard C, Lambotte O. Life threatening steroid-resistant autoimmune anemia successfully treated with rituximab: a case report. Am J Hematol 2009;84:193.
51. Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008;47:1104-1105 (Pubitemid 351865947)
52. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous mani-festations. J Rheumatol 2008;35:2017-2023
53. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008;6:366-373 (Pubitemid 351712824)